As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Harvard Bioscience Inc. The largest reported stake is William Snider's, at 15.97%. 7 filings are on record since July 17, 2025 (Schedule 13D, March 23, 2026).
Sell to companies like Harvard Bioscience Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Leviticus Partners LP · Sole voting: 235,000 · Shared voting: 0 · Sole dispositive: 235,000 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-09-22
- · Holder: Leviticus Partners LP · Percent: 6.5% · SCHEDULE 13G/A
- · Holder: William Snider · Percent: 15.97% · SCHEDULE 13D
- · Holder: Leviticus Partners LP · Percent: 7.6% · SCHEDULE 13G/A
- · Holder: Leviticus Partners LP · Percent: 7.5% · SCHEDULE 13G/A
Harvard Bioscience Inc has 7 Schedule 13D or 13G filings on record since 2025-07-17. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2026-01-29 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 15.97% | 846,000 | SCHEDULE 13D, 2026-03-23 | 2025-12-17 | |
| Leviticus Partners LP | 5.2% | 235,000 | SCHEDULE 13G/A, 2026-09-22 | 2026-09-14 |
| BlackRock, Inc. | 2.5% | 1,113,926 | SCHEDULE 13G/A, 2025-07-17 | 2025-06-30 |
Holding shares or following this stake? See who's behind Harvard Bioscience Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Harvard Bioscience Inc and the records around it.
Harvard Bioscience Inc elsewhere on the record
- Layoff notices Jan 2026
- Who owns it
Companies that share a holder
- Leviticus Partners LP also filed stake reports on 6 other companies: Maris Tech Ltd. (Sep 2026), SEQUANS COMMUNICATIONS (May 2026), UNIVERSAL ELECTRONICS INC (May 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Harvard Bioscience Inc
Get an email when Harvard Bioscience Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Harvard Bioscience Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Harvard Bioscience Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Harvard Bioscience Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Leviticus Partners LP | 235,000 | 0 | 235,000 | 0 | SCHEDULE 13G/A, 2026-09-22 |
The latest filing identifies Harvard Bioscience Inc by CUSIP 416906105 and gives its principal executive office as 84 OCTOBER HILL RD, HOLLISTON, MA 01746 (SCHEDULE 13G/A, 2026-09-22).
Purpose of Transaction (Item 4)
William Snider
The information contained above in Item 1 and Item 3 of this Schedule 13D is incorporated herein by reference. The Reporting Persons acquired the securities of the Issuer in connection with the Loan Agreement. Mr. Snider serves a member of the board of directors of the Issuer and, in such capacity, may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Mr. Snider is a partner of BroadOak Capital Partners and manager of BroadOak Income Fund and BroadOak Fund VI. Subject to the Issuer's Insider Trading Policy and other applicable policies, Mr. Snider may from time to time buy or sell securities of the Issuer as appropriate for his personal circumstances, and may receive compensation from the Issuer, in the form of cash, equity or otherwise, in connection with his service as a director of the Issuer. Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, subject to the agreements described herein, the Reporting Persons, at any time and from time to time, may review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management of the Issuer or the board of directors of the Issuer with respect to the …The first part of Item 4 of the SCHEDULE 13D filed 2026-03-23; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 2.5% | SCHEDULE 13G/A |
| 2025-08-07 | Leviticus Partners LP | 9.2% | SCHEDULE 13G/A |
| 2025-11-03 | Leviticus Partners LP | 7.5% | SCHEDULE 13G/A |
| 2026-02-12 | Leviticus Partners LP | 7.6% | SCHEDULE 13G/A |
| 2026-03-23 | William Snider | 15.97% | SCHEDULE 13D |
| 2026-05-14 | Leviticus Partners LP | 6.5% | SCHEDULE 13G/A |
| 2026-09-22 | Leviticus Partners LP | 5.2% | SCHEDULE 13G/A |
Questions about who owns Harvard Bioscience Inc
Who owns Harvard Bioscience Inc?
On this page, 2 holders' latest ownership filings report 5% or more of Harvard Bioscience Inc: William Snider (15.97%, Schedule 13D, filed 2026-03-23) and Leviticus Partners LP (5.2%, Schedule 13G/A, filed 2026-09-22).
Who are the largest shareholders of Harvard Bioscience Inc?
By the share each holder's latest filing reports, the largest holders of Harvard Bioscience Inc on this page are William Snider (15.97%) and Leviticus Partners LP (5.2%).
When did William Snider buy into Harvard Bioscience Inc?
The filings give report dates, not purchase dates. The earliest filing from William Snider on this page is the Schedule 13D, filed 2026-03-23, reporting 15.97%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Harvard Bioscience Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.